Compare DUOT & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | EOLS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | 39 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.5M | 284.3M |
| IPO Year | 2017 | 2018 |
| Metric | DUOT | EOLS |
|---|---|---|
| Price | $9.00 | $5.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $17.00 | $15.50 |
| AVG Volume (30 Days) | 418.3K | ★ 668.9K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.96 | 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | $27,023,651.00 | ★ $297,176,000.00 |
| Revenue This Year | $50.98 | $13.27 |
| Revenue Next Year | N/A | $17.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 271.16 | 11.61 |
| 52 Week Low | $5.78 | $3.86 |
| 52 Week High | $12.17 | $12.24 |
| Indicator | DUOT | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 63.37 |
| Support Level | $8.89 | $4.02 |
| Resistance Level | $9.60 | $5.52 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 74.45 | 84.17 |
Duos Technologies Group Inc delivers AI-driven technologies, edge computing infrastructure, and energy consulting services to support data-intensive and mission-critical operations. It manages, operates, engineers, software development, customer support and project implementation and management across three market segments, including rail technology deployment, Data Center co-location facilities, and behind-the-meter electrical power provision. It also continues to operate as a technology company which designs, develops, deploys, and operates intelligent technology solutions with a focus on software applications and artificial intelligence (AI) in addition to large projects, consulting, implementation, and asset management.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.